Multiple Myeloma And Cannabinoids
Multiple myeloma is the second most commonly reported malignant disease in the haematopoietic system. Until now, the disease was considered to be incurable (Anderson KC et al., 2011). The CB2 receptor is found in abundance in the bloodstream and in the immune system. Although clinical trials have not yet been conclusively studied, the mechanisms of cannabinoids have been studied for the treatment of multiple myeloma. These studies demonstrated that cannabinoids caused selective apoptosis of multiple myeloma cells by both caspase activation and ceramide accumulation The CB-WIN-55,212-2 mesylate agonist receptor was found to reduce myeloma cell viability by 85%, but but not to affect healthy tissue cells; it slightly reduced B lymphocytes, but did not affect the viability of T lymphocytes (Barbado MV et al., 2017). The cannabinoids PGN-6 and 217 had no effect on the viability of either B or T lymphocytes even at high doses.
Consult your doctor before using this diary supplement on your own responsibility.